Edgewise Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Edgewise Therapeutics announces its 2026 Annual Meeting of Stockholders, detailing director elections, auditor ratification, and executive compensation.
NASDAQ
DEFA14A: Edgewise Therapeutics Corrects Share Count and Director Class in Proxy Statement Supplement
Edgewise Therapeutics issues a supplement to its definitive proxy statement to correct the number of outstanding shares and the class of directors being elected at the annual meeting.
NASDAQ
Edgewise Therapeutics announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation votes.
NASDAQ
Edgewise Therapeutics sets date for annual stockholder meeting, proposes director elections, and seeks ratification of accounting firm appointment.
NASDAQ
Edgewise Therapeutics appoints Arlene Morris, a biotech industry veteran, to its Board of Directors, effective May 6, 2024.
NASDAQ
Edgewise Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 7, 2024, with key proposals including the election of directors, ratification of KPMG LLP as the independent accounting firm, and approval of an amendment to limit officer liability.
NASDAQ
DEF 14A: Edgewise Therapeutics Sets Date for 2024 Annual Meeting, Proposes Officer Liability Amendment
Edgewise Therapeutics will hold its annual stockholder meeting on June 7, 2024, to elect directors, ratify the appointment of KPMG LLP as its independent accounting firm, and vote on an amendment to limit officer liability.